Only in Titles

Search results for: Monoclonal

paperclip

#32745940   2020/07/24 To Up

Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic.


Ankur Jain, Karthik Ramasamy

1972 related Products with: Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic.

50 UG 5 G1 mg100 ug100 ul100ul100μg100ug100 ug/vial1 mg1 mg 50UG

Related Pathways

    No related Items
paperclip

#32745840   2020/07/15 To Up

Quantitative ciprofloxacin on-site rapid detections using quantum dot microsphere based immunochromatographic test strips.

The ciprofloxacin (CIP) abuse has caused many problems threatening to human health. Here, we design the quantum dot microsphere (QDM) based immunochromatographic quantitative CIP test strip: when the sample under detection contains CIP, the QDM-monoclonal antibody (mAb) probes bound with the CIP and cannot be captured by CIP-bovine serum albumin (BSA) conjugation dispersed on the T lines, reducing the fluorescence intensities. These test strips can provide a low detection limit of 0.05 ng/mL and a wide linear detection range from 0.1 ng/mL to 100 ng/mL in high sensitivity and accuracy as well as good selectivity, reproducibility and stability. Moreover, a smartphone based test strip reader with the size of 85 mm × 48 mm × 44 mm is also fabricated using 3-D printing to automatically and quantitatively detect CIP. The whole process of CIP detection can be finished within 15 min, but only cost ~1 RMB (10 cents).
Jing Liu, Bin Wang, Huachuan Huang, Dan Jian, Yunan Lu, Yanke Shan, Shouyu Wang, Fei Liu

2183 related Products with: Quantitative ciprofloxacin on-site rapid detections using quantum dot microsphere based immunochromatographic test strips.

96 Tests n 96 Tests 100tests50 ul100tests500 tests50 ul250tests100tests1T x 10/Kit96 Tests n

Related Pathways

paperclip

#32745254   2020/08/03 To Up

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.

Predicting oncologic outcome is challenging due to the diversity of cancer histologies and the complex network of underlying biological factors. In this study, we determine whether machine learning can extract meaningful associations between oncologic outcome and clinical trial, drug-related biomarker, and molecular profile information. We analyzed therapeutic clinical trials corresponding to 1,102 oncologic outcomes from 104,758 cancer patients with advanced colorectal adenocarcinoma, pancreatic adenocarcinoma, melanoma, and non-small-cell lung cancer. For each intervention arm, a dataset with the following attributes was curated: line of treatment, number of cytotoxic chemotherapies, small-molecule inhibitors, or monoclonal antibody agents, drug class, molecular alteration status of the clinical arm's population, cancer type, probability of drug sensitivity (PDS) (integrating the status of genomic, transcriptomic, and proteomic biomarkers in the population of interest), and outcome. A total of 467 progression-free survival (PFS) and 369 overall survival (OS) data-points were used as training sets to build our machine learning (random forest) model. Cross-validation sets were used for PFS and OS, obtaining correlation coefficients (r) of 0.82 and 0.70 respectively (outcome versus model's parameters). A total of 156 PFS and 110 OS data-points were used as test sets. The Spearman correlation (r ) between predicted and actual outcome was statistically significant (PFS: r =0.879, OS: r =0.878, P<0.0001). The better outcome arm was predicted in 81% (PFS: N=59/73, z=5.24, P<0.0001) and 71% (OS: N=37/52, z=2.91, P=0.004) of randomized trials. The success of our algorithm to predict clinical outcome may be exploitable as a model to optimize clinical trial design with pharmaceutical agents. This article is protected by copyright. All rights reserved.
Alexander V Schperberg, Amélie Boichard, Igor F Tsigelny, Stéphane B Richard, Razelle Kurzrock

2162 related Products with: Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.



Related Pathways

paperclip

#32745149   2020/08/03 To Up

Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.

Human cytomegalovirus (HCMV) is one of the main causative agents of congenital viral infection in neonates. HCMV infection also causes serious morbidity and mortality among organ transplant patients. Glycoprotein B (gB) is a major target for HCMV neutralizing antibodies, yet the underlying neutralization mechanisms remain largely unknown. Here we report that 3-25, a gB-specific monoclonal antibody previously isolated from a healthy HCMV-positive donor, efficiently neutralized 14 HCMV strains in both ARPE-19 cells and MRC-5 cells. The core epitope of 3-25 was mapped to a highly conserved linear epitope on antigenic domain 2 (AD-2) of gB. A 1.8 Å crystal structure of 3-25 Fab in complex with the peptide epitope revealed the molecular determinants of 3-25 binding to gB at atomic resolution. Negative-staining electron microscopy (EM) 3D reconstruction of 3-25 Fab in complex with de-glycosylated postfusion gB showed that 3-25 Fab fully occupied the gB trimer at the N-terminus with flexible binding angles. Functionally, 3-25 efficiently inhibited HCMV infection at a post-attachment step by interfering with viral membrane fusion, and restricted post-infection viral spreading in ARPE-19 cells. Interestingly, bivalency was required for HCMV neutralization by AD-2 specific antibody 3-25 but not the AD-4 specific antibody LJP538. In contrast, bivalency was not required for HCMV binding by both antibodies. Taken together, our results reveal the structural basis of gB recognition by 3-25 and demonstrate that inhibition of viral membrane fusion and a requirement of bivalency may be common for gB AD-2 specific neutralizing antibody.
Xiaohua Ye, Hang Su, Daniel Wrapp, Daniel C Freed, Fengsheng Li, Zihao Yuan, Aimin Tang, Leike Li, Zhiqiang Ku, Wei Xiong, Dabbu Jaijyan, Hua Zhu, Dai Wang, Jason S McLellan, Ningyan Zhang, Tong-Ming Fu, Zhiqiang An

1312 related Products with: Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.

100ug4 Membranes/Box 100ul100ug Lyophilized4 Membranes/Box100ug100ug Lyophilized100ug Lyophilized100ul100ug Lyophilized100ug Lyophilized100ug

Related Pathways

paperclip

#32745103   2020/08/03 To Up

Population genomics identifies a distinct Plasmodium vivax population on the China-Myanmar border of Southeast Asia.

Plasmodium vivax has become the predominant malaria parasite and a major challenge for malaria elimination in the Greater Mekong Subregion (GMS). Yet, our knowledge about the evolution of P. vivax populations in the GMS is fragmental. We performed whole genome sequencing on 23 P. vivax samples from the China-Myanmar border (CMB) and used 21 high-coverage samples to compare to over 200 samples from the rest of the GMS. Using genome-wide single nucleotide polymorphisms (SNPs), we analyzed population differentiation, genetic structure, migration and potential selection using an array of methods. The CMB parasites displayed a higher proportion of monoclonal infections, and 52% shared over 90% of their genomes in identity-by-descent segments with at least one other sample from the CMB, suggesting preferential expansion of certain parasite strains in this region, likely resulting from the P. vivax outbreaks occurring during this study period. Principal component, admixture, fixation index and phylogenetic analyses all identified that parasites from the CMB were genetically distinct from parasites from eastern parts of the GMS (Cambodia, Laos, Vietnam, and Thailand), whereas the eastern GMS parasite populations were largely undifferentiated. Such a genetic differentiation pattern of the P. vivax populations from the GMS parasite was largely explainable through geographic distance. Using the genome-wide SNPs, we narrowed down to a set of 36 SNPs for differentiating parasites from different areas of the GMS. Genome-wide scans to determine selection in the genome with two statistical methods identified genes potentially under drug selection, including genes associated with antifolate resistance and genes linked to chloroquine resistance in Plasmodium falciparum.
Awtum M Brashear, Qi Fan, Yubing Hu, Yuling Li, Yan Zhao, Zenglei Wang, Yaming Cao, Jun Miao, Alyssa Barry, Liwang Cui

1215 related Products with: Population genomics identifies a distinct Plasmodium vivax population on the China-Myanmar border of Southeast Asia.

200 200 1 mg1 mg1100.00 ul

Related Pathways

paperclip

#32745067   2020/08/04 To Up

Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab.

Objectives A matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) method (Mass-Fix) as a replacement for gel-based immunofixation (IFE) has been recently described. To utilize Mass-Fix clinically, a validated automated method was required. Our aim was to automate the pre-analytical processing, improve positive specimen identification and ergonomics, reduce paper data storage and increase resource utilization without increasing turnaround time. Methods Serum samples were batched and loaded onto a liquid handler along with reagents and a barcoded sample plate. The pre-analytical steps included: (1) Plating immunopurification beads. (2) Adding 10 μl of serum. (3) Bead washing. (4) Eluting the immunoglobulins (Igs), and reducing to separate the heavy and light Ig chains. The resulting plate was transferred to a second low-volume liquid handler for MALDI plate spotting. MALDI-TOF mass spectra were collected. Integrated in-house developed software was utilized for sample tracking, driving data acquisition, data analysis, history tracking, and result reporting. A total of 1,029 residual serum samples were run using the automated system and results were compared to prior electrophoretic results. Results The automated Mass-Fix method was capable of meeting the validation requirements of concordance with IFE, limit of detection (LOD), sample stability and reproducibility with a low repeat rate. Automation and integrated software allowed a single user to process 320 samples in an 8 h shift. Software display facilitated identification of monoclonal proteins. Additionally, the process maintains positive specimen identification, reduces manual pipetting, allows for paper free tracking, and does not significantly impact turnaround time (TAT). Conclusions Mass-Fix is ready for implementation in a high-throughput clinical laboratory.
Mindy Kohlhagen, Surendra Dasari, Maria Willrich, MeLea Hetrick, Brian Netzel, Angela Dispenzieri, David L Murray

2636 related Products with: Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab.



Related Pathways

paperclip

#32744917   2020/08/03 To Up

Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.

Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.
Khan Sharun, Ruchi Tiwari, Mohd Iqbal Yatoo, Shailesh Kumar Patel, Senthilkumar Natesan, Jaideep Dhama, Yashpal S Malik, Harapan Harapan, Raj Kumar Singh, Kuldeep Dhama

2536 related Products with: Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.

100ug1000 tests100ug100ul200ug100ul100ug50 ug 50 ug 1,000 tests200ul50 ug

Related Pathways

paperclip

#32744544   2020/08/03 To Up

A microwell array structured surface plasmon resonance imaging gold chip for high-performance label-free immunoassay.

Surface plasmon resonance imaging (SPRi) offers a compelling method for high-throughput, real-time, and label-free biomolecular interaction studies and immunoassays, but its performance suffers from limited intrinsic sensitivity and low-contrast SPRi images. Herein we report a high-performance SPRi chip featuring patterned microwell array constructed by photolithography of adhesive polydopamine (PDA) thin film on conventional gold chip. The chip allows for the facile construction of region-defined sensing array on its surface with improved intrinsic SPRi sensitivity due to the intensified surface plasmon wave (SPW) in the microwells. The immunoassay performance of the as-designed SPRi chip is evaluated by using anti-ochratoxin A (anti-OTA) monoclonal antibody as a model target. The results show that this microwell array structured gold chip exhibits ca. 18%-32% higher signal intensity than the conventional gold chip when detecting anti-OTA at different concentrations, and the noise remains at the same level, showing enhanced intrinsic sensitivity. Meanwhile, this microwell-structured chip affords clear and high-contrast SPRi images with well-defined sensing areas, which greatly facilitates the extraction and quantitative analysis of detection signals while efficiently suppressing the disturbance from background areas.
Yihong Mei, Ling Li, Nan Chen, Changyin Zhong, Weihua Hu

2316 related Products with: A microwell array structured surface plasmon resonance imaging gold chip for high-performance label-free immunoassay.

1 mg4 Sample Kit2 Sample Kit

Related Pathways

paperclip

#32744429   2020/08/03 To Up

MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

Previously, we developed a monoclonal antibody (mAb) NJ001 that binds to the antigen SP70 in human non-small cell lung cancer (NSCLC) cells and showed it could inhibit lung adenocarcinoma (AD) growth. Here, we investigated the effect and mechanisms of NJ001 in lung AD metastasis.
Chunrong Gu, Ying Luo, Shichang Zhang, Jian Xu, Jiexin Zhang, Huanyu Ju, Jingping Liu, Lixia Zhang, Yan Zhang, Lei Wu, Erfu Xie, Ting Xu, Shiyang Pan

1678 related Products with: MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

25 x 2 ml100tests30µg/vial48 assays

Related Pathways

paperclip

#32744401   2020/08/03 To Up

A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewisx.

Siglecs are members of the immunoglobulin gene family containing sialic acid binding N-terminal domains. Among them, Siglec-8 is expressed on various cell types of the immune systemsuch as eosinophils, mast cells and weakly on basophils. Cross-linking of Siglec-8 with monoclonal antibodies triggers apoptosis in eosinophils and inhibits degranulation of mast cells, making Siglec-8 a promising target for the treatment of eosinophil- and mast cell-associated diseases such as asthma.The tetrasaccharide 6'-sulfo-sialyl Lewisx(1a) has been identified as a specific Siglec-8 ligand in glycan array screening. Here, we describe an extended study enlightening the pharmacophores in 6'-sulfo-sialyl Lewisx(1a) and the successful development of a high-affinity mimetic. Retaining the neuraminic acid core, the introduction of a carbocyclic mimetic of the Gal moiety and a sulfonamide substituent in the 9-position gave a 20-fold improved binding affinity. Finally, the residence time, usually is the Achilles tendon of carbohydrate/lectin interactions, could be improved.
Blijke Kroezen, Gabriele Conti, Benedetta Girardi, Jonathan Cramer, Xiaohua Jiang, Said Rabbani, Jennifer Müller, Maja Kokot, Enrico Luisoni, Daniel Ricklin, Oliver Schwardt, Beat Ernst

1408 related Products with: A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewisx.

1 G50 ug5 mg500 MG250 mg10 mg10 mg96T 1 G100ug Lyophilized

Related Pathways